Johnson R E, Johnson J C, Kloberdanz S J, Morrill M J
College of Podiatric Medicine and Surgery, University of Osteopathic Medicine and Health Sciences, Des Moines, IA 50312.
J Am Podiatr Med Assoc. 1991 May;81(5):253-7. doi: 10.7547/87507315-81-5-253.
The authors review the literature and report the mechanisms of action, chemical properties, pharmacokinetics, adverse effects, and clinical studies of recombinant alpha-interferon. The authors believe that clinical trials should be performed with recombinant alpha-interferon therapy on verruca plantaris to prove or disprove the effectiveness of interferon as a potential treatment modality for these commonly encountered lesions.